Surrozen, Inc. (SRZN)

NASDAQ: SRZN · IEX Real-Time Price · USD
2.03
+0.01 (0.50%)
At close: Oct 3, 2022 2:01 PM
2.44
+0.41 (20.20%)
After-hours: Oct 3, 2022 6:52 PM EDT
0.50%
Market Cap 71.30M
Revenue (ttm) n/a
Net Income (ttm) -50.85M
Shares Out 35.12M
EPS (ttm) -1.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,209
Open 2.03
Previous Close 2.02
Day's Range 2.03 - 2.21
52-Week Range 1.92 - 10.35
Beta n/a
Analysts Buy
Price Target 14.96 (+636.9%)
Earnings Date Aug 10, 2022

About SRZN

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody t... [Read more...]

Industry Biotechnology
Founded 2015
Employees 83
Stock Exchange NASDAQ
Ticker Symbol SRZN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for SRZN stock is "Buy." The 12-month stock price forecast is 14.96, which is an increase of 636.95% from the latest price.

Price Target
$14.96
(636.95% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Precl...

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Surrozen , Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and...

1 week ago - GlobeNewsWire

Surrozen Reports Second Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt p...

1 month ago - GlobeNewsWire

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

SOUTH SAN FRANCISCO, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a clinical-stage company pioneering targeted therapeutics that selectively act...

3 months ago - GlobeNewsWire

Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and re...

4 months ago - GlobeNewsWire

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

SOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a clinical-stage company pioneering targeted therapeutics that selectively acti...

4 months ago - GlobeNewsWire

Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a S...

Results highlight potential for novel approach to treating IBD with Wnt mimetic Results highlight potential for novel approach to treating IBD with Wnt mimetic

4 months ago - GlobeNewsWire

Surrozen Reports First Quarter 2022 Financial Results

On Track to Initiate Phase 1 Clinical Trials in Healthy Volunteers for SZN-1326 and SZN-043 in the Third Quarter of 2022 On Track to Initiate Phase 1 Clinical Trials in Healthy Volunteers for SZN-1326 a...

4 months ago - GlobeNewsWire

Surrozen to Present at the BofA Securities 2022 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pa...

4 months ago - GlobeNewsWire

Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association f...

Preclinical data suggest that SZN-413 can simultaneously address retinal non-perfusion and leakage in blood vessels in retinal vascular diseases Preclinical data suggest that SZN-413 can simultaneously ...

5 months ago - GlobeNewsWire

Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results

On Track to Initiate Phase 1 Clinical Trials in Healthy Volunteers for SZN-1326 and SZN-043 in the Third Quarter of 2022 On Track to Initiate Phase 1 Clinical Trials in Healthy Volunteers for SZN-1326 a...

6 months ago - GlobeNewsWire

Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline

-Initiation of Phase 1 clinical trials of SZN-1326 and SZN-043 expected in third quarter 2022

8 months ago - GlobeNewsWire

Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

Surrozen to provide a business update including discussion of pipeline advancements Surrozen to provide a business update including discussion of pipeline advancements

8 months ago - GlobeNewsWire

Surrozen Reports Third Quarter 2021 Financial Results

Product Candidates SZN-1326 and SZN-043 Advance Toward Initiation of Clinical Studies in 2022

10 months ago - GlobeNewsWire

Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American ...

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and r...

10 months ago - GlobeNewsWire

Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc., (NASDAQ: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway,...

10 months ago - GlobeNewsWire

Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc., (Nasdaq: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway,...

10 months ago - GlobeNewsWire

Surrozen's Inflammatory Bowel Disease Candidate Shows Encouraging Preclinical Action

Surrozen Inc (NASDAQ: SRZN) announced that preclinical data from its inflammatory bowel disease (IBD) program, SZN-1326, were presented during the 2021 United European Gastroenterology Week. Related:   ...

11 months ago - Benzinga

Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week

Encouraging preclinical data support continued advancement of SZN-1326 towards first in human clinical studies in 2022 Encouraging preclinical data support continued advancement of SZN-1326 towards firs...

11 months ago - GlobeNewsWire

Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources

SOUTH SAN FRANCISCO, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc. (Nasdaq: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, ...

1 year ago - GlobeNewsWire

Here's why Surrozen shares are up more than 50% on Tuesday

Almost a month after Surrozen Inc (NASDAQ: SRZN) completed its business combination with a special purpose acquisition company (SPAC), Consonance-HFW Acquisition Corp, Stifel assumed coverage of the bio...

1 year ago - Invezz

See Why Surrozen Stock Is Surging On Tuesday

Stifel initiated coverage of Surrozen Inc (NASDAQ: SRZN) with a Buy rating and $19 price target.  The regenerative medicine biotech started trading recently on NASDAQ via SPAC deal with Consonance-HFW A...

1 year ago - Benzinga

Surrozen Debuts as Publicly Traded Leader in Wnt Biology and Tissue Regeneration

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Surrozen, Inc. (“Surrozen”), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today ...

1 year ago - Business Wire

Surrozen to Present at Canaccord Genuity's 41st Annual Growth Conference

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc. (Nasdaq: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, t...

1 year ago - GlobeNewsWire

New Surrozen to Trade on Nasdaq as “SRZN”

PRINCETON, N.J.--(BUSINESS WIRE)--Consonance-HFW Acquisition Corp. (NYSE American LLC: CHFW) (“CHFW”) today announced that, upon the Domestication and the consummation of its pending business combinatio...

1 year ago - Business Wire

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Consonance-HFW Acquisition Corp. - CHFW

NEW YORK, May 15, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action ...

1 year ago - PRNewsWire